Evidence Table E61. Binge eating disorder drug treatment – part 7

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Arnold, 200266 | CGI-SHAM-D | CGI-S, mean (SD):G1: 4.2 (0.4)G2: 4.3 (0.6)(P = NS)HAM-D, mean (SD):G1: 4.8 (4.3)G2: 4.2 (2.9)(P = NS) | CGI-S, mean (SD):G1: 2.2 (1.4)G2: 3.3 (1.4)Diff between groups (P = NR)Diff between groups in change over time (time trend analysis, P = 0.032; endpoint analysis, P = 0.012), G1 better than G2HAM-D, mean (SD):G1: 2.6 (3.0)G2: 5.5 (4.1)Diff between groups (P = NR)Diff between groups in change over time (time trend analysis, P = NS; endpoint analysis, P = 0.003), G1better than G2 |
| Brownley, 201367 | Quick Inventory of Depressive Symptomatology; QIDS-SR | QIDS-SRbaselineG1: 7.1 (5.4)G2: 8.1 (3.0)G3: 5.7 (3.0)p = 0.99 | QIDS-SRMonthly rate of changeG1:-0.30 (0.21)G2: -0.41 (0.19)G3: -0.03 (0.21)p = ns |
| Guerdjikova, 200968 | CGI-SYBOCS-BEYBOCS BE ObsessionsYBOCS BE CompulsionsMADRSBIS TotalBIS AttentionBIS MotorBIS Nonplanning | CGI-S (M,SD)G1: 4.46 (0.65)G2: 4.52 (0.59)YBOCS BE(M,SD)G1: 19.42 (4.12)G2: 20.68 (4.72)YBOCS BE Obsessions (M,SD)G1: 9.04 (2.62)G2: 9.84 (2.98)YBOCS-BE Compulsison (M,SD)G1: 10.38 (2.30)G2: 10.84 (2.01)MADRS (M,SD)G1: 3.85 (3.83)G2: 3.04 (3.35) | CGI-S (M,SD):G1: 2.38 (1.44)G2: 2.20 (1.32)Diff between groups (P = 0.519) Diff between groups in change over time (P =0.759)YBOCS BE(M,SD)G1: 8.68 (7.91)G2: 7.08 (6.55)Diff between groups (p=0.102)Diff between groups in change over time (p=0.109)YBOCS BE Obsessions (M,SD)G1: 4.52 (4.11)G2: 3.80 (3.30)Diff between groups (p=0.111) |

Evidence Table E61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Guerdjikova, 200968(continued) |  | BIS Total (M,SD)G1: 66.23 (10.56)G2: 35.88 (9.62)BIS Attention (M,SD)G1: 17.88 (3.71)G2: 11.50 (3.87)BIS Motor (M,SD)G1: 22.19 (3.96)G2: 12.60 (3.51)BIS Nonplanning (M,SD)G1: 26.15 (5.24)G2: 12.24 (4.16) | Diff between groups in change over time (p=0.188)YBOCS-BE Compulsison (M,SD)G1: 4.16 (4.00)G2: 3.28 (3.40)Diff between groups (p=0.144)Diff between groups in change over time (p=0.079)MADRS (M,SD)G1: 2.16 (3.34)G2: 0.56 (1.23)Diff between groups (p=0.472)Diff between groups in change over time (p=0.944)BIS Total G1: 55.60 (23.41)G2: 46.70 (28.22)Diff between groups (p=0.524)Diff between groups in change over time (p=0.462)BIS AttentionG1: 17.18 (3.59)G2: 16.20 (4.82)Diff between groups (p=0.649)Diff between groups in change over time (p=0.440)BIS MotorG1: 21.41 (5.02)G2: 20.86 (6.85)Diff between groups (p=0.521)Diff between groups in change over time (p=0.849)BIS NonplanningG1: 24.59 (4.97)G2: 21.31 (6.82)Diff between groups (p=0.642)Diff between groups in change over time (p=0.229) |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Guerdjikova, 200869 | Hamilton Depression Rating Scale (HAM-D)Clinical Global Impression (CGI)-severity-improvement | HAM-D, M (SD)G1: 4.6 (3.75)G2: 5.7 (4.5)p=NSCGI-severity, M (SD)G1: 4.8 (0.7)G2: 4.7 (0.7)p=NS | HAM-D, M (SD)G1: 2.4 (2.9)G2: 4.8 (5.1) Time-trend analysisEstimate between-group difference in 12-week change (95% CI): 1.3 (-1.0, -3.5)chi-square: 1.21p=0.262Endpoint analysisEstimate between-group difference in change from BL to final visit (95% CI): 1.8 (-0.3, -3.9)t=1.25p=0.097CGI-severity, M (SD) G1: 2.3 (1.3)G2: 3.2 (1.4)Time-trend analysisEstimate between-group difference in 12-week change (95% CI): 0.9 (0.1, -1.8)chi-square: 4.56p=0.029Endpoint analysisEstimate between-group difference in change from BL to final visit (95% CI): 1.0 (0.1, -1.9)t=2.56p=0.026CGI-improvement scale:"The mean final CGI-Improvement Scale at endpoint was rated much or very much improved in 17 (85%) of G1 as compared with 9 (39.1%) of G2 (p=0.029)." |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Guerdjikova, 201270 | Clinical Global Impression Severity for depressive disorders (CGI-S-DD)Clinical Global Impression Improvement for depressive disorders (CGI-I-DD)Inventory of Depressive Symptoms (IDC)Hamilton Anxiety Scale (HAM-A) | CGI-S-DDG1: 4.3 (0.7)G2: 4.2 (0.7)p = NRIDS-CG1: 35.6 (7.9)G2: 35.4 (5.4)p = NRHAM-AG1: 16.9 (9.1)G2: 16.2 (5.7)p = NR | CGI-S-DDG1: 2.3 (1.3)G2: 2.9 (1.0)Longitudinal Analysisd = 0.82p = 0.01Endpoint Analysisd = 0.68p = 0.03CGI-I-DDG1: 1.7 (1.1)G2: 2.4 (1.4)Endpoint Analysisd = 0.34p = 0.30IDS-CG1: 19.1 (11.5)G2: 21.6 (12.7)Longitudinal Analysisd = 0.18p = 0.58Endpoint Analysisd = 0.33p = 0.3250% or greater reduction IDS-C (response)G1: 11G2: 8p = 0.19IDS-C < 12 at endpoint (remission)G1: 5G2: 4p = 0.71HAM-AG1: 9.6 (9.0)G2: 7.2 (6.5)Endpoint Analysisd = 0.17p = 0.60 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Hudson, 199871 | Hamilton depression scale score (HRDS) | HDRS, M (SD)G1: 4.4 (3.6)G2: 4.1 (3.7)p=NR, NS | HDRSTreatment-by-time interaction: -0.401 (SE 0.359)p=0.27 |
| Leombruni, 200872 | Beck Depression Inventory (BDI)Clinical Global Impression (CGI) | BDIG1: 11.1 (4.5)G2: 13.3 (7.0)CGIG1: 4.0 (0.7)G2: 3.8 (0.6) | BDIT8G1:8.7 (4.1)G2: 8.6 (5.2)T12G1: 7.1 (4.1)G2: 9.5 (5.9)T24G1: 8.4 (6.2)G2: 9.9 (5.9)time effect p<0.001time x group effect p<0.640CGIT8G1: 3.4 (0.8)G2: 3.1 (0.8)T12G1: 2.9 (1.0)G2: 3.0 (1.0) T24G1: 3.1 (0.9)G2: 2.8 (0.9)Time effect p<0.001Time x group effect p<0.393 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 200773 | Hamilton depression scale (HDRS)Clinical Global Impression (CGI) severity | HDRS, mean (SD):G1: 2.0 (2.4)G2: 3.3 (3.6)CGI severity, mean (SD):G1: 4.2 (0.4)G2: 4.4 (0.6) | HDRS:Longitudinal AnalysisEstimate (mean change btwn g1 - g2): 0.5895% CI: -1.33 to 2.49X^2: 0.36p: 0.551Endpoint AnalysisEstimate (mean change btwn g1-g)2: -0.1595% CI: -2.13 to 1.83t: 0.15p: 0.879CGI severityLongitudinal AnalysisEstimate (mean change btwn g1 - g2): -1.1295% CI: -2.01 to -0.22X^2: 6.03p: 0.015Endpoint AnalysisEstimate (mean change btwn g1-g)2: -1.2095% CI: -1.90 to -0.50t: 3.48p: 0.013 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 200674 | Hamilton Rating Scale for Depression (HAM-D)Clinical Global Impression Severity (CGI-S) | HAM-D, mean (SD):G1: 4.4 (SD 4.4)G2: 4.9 (SD 5.5)p=NR, NSCGI-S, mean (SD):G1: 4.7 (0.5)G2: 4.5 (0.7)p=NR, NS | HAM-DLongitudinal analysisG1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -0.18 (95% CI -2.79 to 2.42)p=0.892Endpoint analysisG1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): 2.13 (95% CI -0.78 to 5.04)p=0.147CGI-SLongitudinal analysisG1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -1.43 (95% CI -2.12 to -0.75)p<0.001Endpoint analysisG1: NRG2: NR |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 200674(continued) |  |  | Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): -0.79 (95% CI -1.57 to 0.00)p=0.049 |
| McElroy, 200375 | Hamilton Rating Scale for Depression (HAM-D)Clinical Global Impression Severity (CGI-S) | HAM-D score, mean (SD)G1: 3.1 (3.2)G2: 2.7 (3.7)p=NR, NSCGI-S score, mean (SD)G1: 4.5 (0.7)G2: 5.0 (0.7)p = 0.033 | HAM-D score, mean (SD)G1: 1.4 (2.3)G2: 1.9 (3.1)Time Trend Analysis:Mean difference between groups in rate of change: -1.05 (SE 0.54)p=0.053Endpoint Analysis:Mean difference between groups in change from baseline to 6wk: -2.04 (SE 0.97)p = 0.10CGI-S, mean (SD)G1: 2.4 (1.4)G2: 3.6 (1.7)Time Trend Analysis:Mean difference between groups in rate of change: -0.475 (SE 0.217)p = 0.28Endpoint Analysis:Mean difference between groups in change from BL to 6wk: -0.545 (SE 0.513)p = 0.29 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 200376 | Clinical Global Impression Severity Scale (CGI-S)Hamilton Depression Rating Scale (HDRS) | CGI Severity Scale, mean (SD)G1: 4.7 (0.9)G2: 4.9 (0.8)p = NSHDRS, mean (SD)G1: 5.9 (5.1)G2: 5.8 (4.8)p = NS | CGI Severity Scale, mean (SD)G1: NRG2: NRDiff between groups, p = 0.01Diff between groups in rate of change, p = 0.02HDRS, mean (SD)G1: NRG2: NRDiff between groups, p = NRDiff between groups in rate of change, p = 0.28 |
| McElroy, 200077 | Hamilton depression rating scale (HDRS)Clinical Global Impression (CGI)- severity (CGI-S)- improvement (CGI-I) | HDRS, mean (SD):G1: 6.4 (3.9)G2: 7.5 (8.4) | HDRS:Diff in change between G1 & G2, mean: 1.33SE: 1.00p = 0.19CGI-S:Diff in change between G1 & G2, mean: -1.007SE: 0.183p < 0.001G1 better than G2CGI-I:Diff in change between G1 & G2, mean: 0.929SE: 0.929p <0.001G1 better than G2 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 201178 | MADRS: Montgomery Asberg depression rating scaleCGI-S: Clinical global impression-severity scaleCGI-I: Clinical global impression-improvement scale | MADRS, mean (SD):G1: 1.8 (2.0)G2: 1.2 (1.4)p = 0.30CGI-S, mean (SD):G1: 4.9 (0.8)G2: 4.8 (0.9)p = 0.71CGI-I, mean (SD):G1: 0.40 (1.23)G2: 1.0 (1.78)p = 0.22 | Endpoint Analysis:CGI-S, mean (SD):G1: 2.7 (1.7)G2: 3.5 (1.4)p = 0.09CGI-I, mean (SD):G1: 2.1 (1.1)G2: 2.6 (1.1)p = 0.96MADRS, mean (SD):G1: 1.4 (2.5)G2: 1.8 (1.9)p = 0.15 |
| McElroy, 200779 | Barrett Impulsiveness Scale (BIS-11)Hamilton Anxiety Scale (HAM-A)Montgomery Asberg depression rating scale (MDRS)Clinical global impression-severity scale (CGI-S) | BIS-11, mean (SD)Overall G1: 64.2 (11.5)G2: 65.7 (11.2)Motor Impulsiveness, mean (SD)G1: 22.8 (4.7)G2: 23.1 (4.3)Nonplanning Impulsiveness, mean (SD)G1: 25.4 (5.3)G2: 25.8 (5)Attentional Impulsiveness, mean (SD)G1: 16.0 (4.2)G2: 16.8 (4.5)HAM-A, mean (SD)G1: 5.1 (4.8)G2: 5.5 (5.1)CGI-S, mean (SD)G1: 4.8 (0.9)G2: 4.8 (0.9) | BIS-11, mean (SD) change from baselineOverall G1: -3.9 (9.0)G2: -1.4 (7.9)Endpoint Analysis: p < 0.001Longitudinal Analysis, rate of change: p = 0.003Motor Impulsiveness, mean (SD) change from baselineG1: -1.8 (3.8)G2: -0.9 (3.7)Endpoint Analysis: p = 0.004Longitudinal Analysis, rate of change: p = 0.006Nonplanning Impulsiveness, mean (SD) change from baselineG1: -1.6 (4.5)G2: 0.01 (3.7)Endpoint Analysis: p < 0.001Longitudinal Analysis, rate of change: p < 0.001 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 200779(continued) |  |  | Attentional Impulsiveness, mean (SD) change from baselineG1: -0.6 (3.6)G2: -0.5 (3.1)Endpoint Analysis: p = 0.230Longitudinal Analysis, rate of change: p = 0.835HAM-A, mean (SD) change from baselineG1: -0.7 (4.9)G2: -1.3 (4.5)Endpoint Analysis, p = 0.493Longitudinal Analysis, rate of change: p = 0.143CGI-I, mean (SD) change from baselineG1: -2.2 (1.6)G2: -1.1 (1.4)Endpoint Analysis, p <0.001Longitudinal Analysis, rate of change: p < 0.001 |
| McElroy, 201380 | Beck Depression Inventory (BDI)Clinical Global Impressions - Severity (CGI-S) | BDI, mean (SD)G1: 3.7 (SD 2.8) G2: 4.7 (SD 4.1)p=0.29CGI-Severity, mean (SD)G1: 4.2 (SD 0.8)G2: 4.4 (SD 0.7)p=0.41 | BDI, mean change (SD) from baseline to endpointG1: -0.7 (SD 3.5) G2: -2.4 (SD 4.1)p=0.09CGI-Severity, mean change (SD) from baseline to endpoint:G1: -1.6 (SD 1.6) G2: -2.1 (SD 1.3)p=0.19 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 201581 | YBOCS-BEBarratt Impulsiveness Scale (BIS-11)SF-12 Aggregate Physical Health Component Summary ScoreSF-12 Aggregate mental health component summary scoreMADRS scoreHAM-A score | YBOCS-BE scoreG1: 20.7 (SD 4.87)G2: 19.5 (SD 5.19)G3: 19.8 (SD 5.48)G4: 20.9 (SD 4.61)BIS-11G1: 61.8 (SD 10.70)G2: 61.0 (SD 9.84)G3: 61.4 (SD 12.69)G4: 63.1 (SD 13.22)MADRS scoreG1: 2.9 (SD 3.02)G2: 3.6 (SD 3.29)G3: 3.7 (SD 3.94)G4: 3.4 (SD 3.39)HAM-A scoreG1: 2.3 (SD 2.32)G2: 2.3 (SD 2.60)G3: 2.5 (SD 3.22)G4: 2.5 (SD 3.01) | 11wk YBOCS-BE, LS change, mean (SE)G1: -15.0 (SE 0.84)G2: -15.3 (SE 0.83)G3: -17.0 (SE 0.83)G4: -12.0 (SE 0.87)11wk YBOCS-BE, Difference from placebo, mean (SE)G1: -2.97 (SE 1.203)G2: -3.25 (SE 1.204)G3: -4.93 (SE 1.202)G4: N/A11wk YBOCS-BE: Significant difference compared with placeboG1 p=0.01G2 p=0.008G3 p<0.001G4 N/A11wk BIS-11, LS change, mean (SE)G1: -5.8 (SE 1.05)G2: -5.2 (SE 1.05)G3: -6.9 (SE 1.05)G4: -3.1 (SE 1.09)11wk BIS-11, Difference from placebo, mean (SE)G1: -2.7 (SE 1.52)G2: -2.1 (SE 1.51)G3: -3.7 (SE 1.51)G4: N/A11wk BIS-11: Significant difference compared with placeboG1 p=0.08G2 p=0.17G3 p=0.02G4 N/A |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 201581(continued) |  |  | 11wk MADRS, LS change, mean (SE)G1: -1.9 (SE 0.34)G2: -1.3 (SE 0.33)G3: -1.6 (SE 0.33)G4: -1.7 (SE 0.35)11wk MADRS, Difference from placebo, mean (SE)G1: -0.15 (SE 0.484)G2: 0.49 (SE 0.480)G3: 0.14 (SE 0.480)G4: N/A11wk MADRS, Significant difference compared with placeboG1 p=0.75G2 p=0.31G3 p=0.77G4 N/A11wk HAM-A, LS change, mean (SE)G1: -0.9 (SE 0.29)G2: -1.1 (SE 0.29)G3: -0.6 (SE 0.29)G4: -1.5 (SE 0.30)11wk HAM-A, Difference from placebo, mean (SE)G1: -0.9 (SE 0.29)G2: -1.1 (SE 0.29)G3: -0.6 (SE 0.29)G4: -1.5 (SE 0.30)11wk HAM-A, Significant difference compared with placeboG1 p=0.20G2 p=0.33G3 p=0.05G4 N/A |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Pearlstein, 200382 | Beck Depression Inventory (BDI)Hamilton Depression Scale (HAM-DHopkins Symptom Checklist (SCL-90)Clinical Global Impression Scale (CGI) | BDI (M, SD):G1: 0.44 (0.22)G2: 0.68 (0.57)(P = NS)HAM-D (M,SD):G1: 10.78 (9.22)G2: 14.27 (12.40)(P = NS)SCL-90 (M,SD):G1: 0.62 (0.33)G2: 0.85 (0.55)(P = NS)CGI-Severity:G1: NRG2: NR | BDI (M,SD):G1: 0.32 (0.30)G2: 0.37 (0.26)Diff between groups (P = NR)Change over time for both groups: (P < 0.01)Diff between groups in change over time (P = NS)HAM-D (M,SD):G1: 9.38 (9.71)G2: 7.38 (6.16)Diff between groups (P = NR)Change over time for both groups: (P = NS)Diff between groups in change over time (P = NS) SCL-90 (M, SD):G1: 0.30 (0.29)G2: 0.40 (0.29)Diff between groups (P = NR)Change over time for both groups: (P < 0.001)Diff between groups in change over time (P = NS)CGI no improvment:G1: 0G2: 4)p<0.07 |
| Shire, 201483,84 | Y-BOCS-BE total | G1: 21.8G2: 21.5 | Change in Y-BOCS-BE total: G1: -15.68 G2: -8.28Diff: -7.4 (-8.9 to -5.9)(p < 0.001) |
| Shire, 201484,85 | Y-BOCS-BE total | G1: 21.1G2: 21.5 | Change in Y-BOCS-BE total: G1: -15.36 G2: -7.42Diff: -7.9 (-9.5 to -6.4)(p < 0.001) |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| White, 201386 | Beck Depression Inventory (BDI)Food Craving Inventory (FCI) | Beck Depression Inventory (BDI)G1: 13.4 (SD 9.8)G2: 10.8 (SD 6.1)Food Craving Inventory (FCI)G1: 2.6 (SD 0.6)G2: 2.4 (SD 0.7) | 8wk Beck Depression Inventory (BDI)G1: 8.0 (SD 8.3)G2: 8.7 (SD 7.2)Mixed effects model medication effectF=0.04, p=0.848wk Food Craving Inventory (FCI)G1: 2.0 (SD 0.6)G2: 2.0 (SD 0.6)Mixed effects model medication effectF=0.10, p=0.76 |